C4 Therapeutics, Inc.
CCCC · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $36.0M | $35.6M | +1.0% |
| Operating income | −$115M | −$120M | +3.7% |
| Net income | −$105M | −$105M | +0.3% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $8.50M | $11.2M | −24.1% |
| Operating income | −$24.6M | −$34.4M | +28.5% |
| Net income | −$21.8M | −$32.2M | +32.3% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was C4 Therapeutics's revenue in FY2025?
- $36.0M in FY2025 (Fiscal year ended Dec 31, 2025), +1.0% vs $35.6M a year earlier, per its 10-K filed Feb 2026.
- Was C4 Therapeutics profitable in FY2025?
- No: net income was −$105M and operating income −$115M in FY2025.
- What was C4 Therapeutics's revenue in Q3 2026?
- $8.50M (−24.1% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.